Different levels of hepatitis C virus adsorption by dialysis membranes during hemodialysis therapy

宏尚, 小寺; 篤, 大橋; 滋, 中井; 誠, 福田; 重樹, 大西; 正知, 八城; 邦浩, 鍋島; 和隆, 村上; 亮, 富田; みどり, 長谷川; 能之, 比企; 敏, 杉山

doi:10.4009/jsdt.43.55

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with this result, our HCV removal rates using HPC-SPS were very high. Using the mathematical model of Kotera et al, it can be expected that the HCV level before the treatment will be significantly reduced by approximately 5-fold [21,22]. Alternatively, increasing the number of perfusions may decrease the amount of HCV.…”

Section: Discussionmentioning

confidence: 99%

Development of a Leukocyte Removal Filter for Hepatitis C Therapy and the Possibility of Multipurpose Treatment

Fueda¹,

Kotera²

2021

IJBSE

Self Cite

View full text Add to dashboard Cite

Hepatitis C virus infects and causes inflammation in extrahepatic organs and the liver. Patients with chronic hepatitis C disease receive interferon-based treatment, and both interferon and interferon-free therapies are expensive. We attempted to eliminate hepatitis C virus-infected cells using extracorporeal circulation with a unique filter. We created two types of the filters with syndiotactic polystyrene (SPS) resin sheets in a solution that dissolved hydroxypropyl cellulose (HPC) and cellulose acetate (CA) in oleyl alcohol, respectively. First, hepatitis C virus-positive cells were confirmed in the blood and mononuclear cells of hepatitis C virus-infected volunteers, showing that mononuclear cells phagocytosed the hepatitis C virus. Next, we extracted blood from three healthy volunteers and examined the blood cell removal rate using various filters. The HPC-SPS (fiber diameter, 3.5 µm) showed the highest mononuclear cell removal rate and the lowest platelet removal rate. HPC-SPS reduced hepatitis C virus-positive cells in patients with the hepatitis C virus, and the removal rate of monocytes containing the hepatitis C virus was 77.2%. Thus, HPC-SPS may serve as filter to remove mononuclear cells and granulocytes from blood. Although a technique using extracorporeal circulation is required to apply HPC-SPS, the technical cost is lower than IFN-free drug therapy. We believe that HPC-SPS can be utilized for the treatment of HCV-and leukocyte-related diseases.

show abstract

Section: Discussionmentioning

confidence: 99%